Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, Myers DT, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan J, Stein GT, Murchie E, Zarrinkar PP, Janes MR, Li LS, Liu Y, Hata AN, Benes CH. Misale S, et al. Among authors: stein gt. Clin Cancer Res. 2019 Jan 15;25(2):796-807. doi: 10.1158/1078-0432.CCR-18-0368. Epub 2018 Oct 16. Clin Cancer Res. 2019. PMID: 30327306
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ, Stein GT, Greninger P, Maves YK, Saunders LR, Dylla SJ, Costa C, Boikos SA, Leverson JD, Souers AJ, Krystal GW, Harada H, Benes CH, Faber AC. Lochmann TL, et al. Among authors: stein gt. Clin Cancer Res. 2018 Jan 15;24(2):360-369. doi: 10.1158/1078-0432.CCR-17-1606. Epub 2017 Nov 8. Clin Cancer Res. 2018. PMID: 29118061 Free PMC article.
Differential Effector Engagement by Oncogenic KRAS.
Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L, Bess M, Cheng KT, Lee CS, Lee LC, Fellmann C, Stephens R, Luo J, Lowe SW, Benes CH, McCormick F. Yuan TL, et al. Among authors: stein gt. Cell Rep. 2018 Feb 13;22(7):1889-1902. doi: 10.1016/j.celrep.2018.01.051. Cell Rep. 2018. PMID: 29444439 Free PMC article.
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
Heisey DAR, Lochmann TL, Floros KV, Coon CM, Powell KM, Jacob S, Calbert ML, Ghotra MS, Stein GT, Maves YK, Smith SC, Benes CH, Leverson JD, Souers AJ, Boikos SA, Faber AC. Heisey DAR, et al. Among authors: stein gt. Clin Cancer Res. 2019 Mar 1;25(5):1664-1675. doi: 10.1158/1078-0432.CCR-18-0277. Epub 2018 Oct 22. Clin Cancer Res. 2019. PMID: 30348635
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC. Dalton KM, et al. Among authors: stein gt. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118. Proc Natl Acad Sci U S A. 2021. PMID: 33762304 Free PMC article.
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC. Cai J, et al. Among authors: stein gt. Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095. Cell Rep. 2022. PMID: 35905710 Free PMC article.